Phaseline

Targets › HRH2

HRH2 (Histamine H2 receptor): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 2 Phase 4, 1 Phase 3; Gastroenterology, Other, Immunology; next expected readout Dec 2027.

G protein-coupled receptor for histamine, primarily mediating gastric acid secretion. Predominantly expressed in the gastric mucosa, couples to G(s) G alpha proteins upon histamine binding, leading to activation of adenylate cyclase and increased intracellular cyclic AMP (cAMP) levels. (UniProt, P25021)

Open in Phaseline: the race on HRH2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Stony Brook UniversityFamotidine
Histamine H2 receptor antagonist
HRH2Phase 4DyspepsiaDec 2027
University of WashingtonCimetidine
Histamine H2 receptor antagonist
HRH2Phase 4PostpartumSep 2028
The University of Texas Medical Branch, GalvestonFamotidine
Histamine H2 receptor antagonist
HRH2Phase 3Burn ScarDec 2027

Conditions

Dyspepsia (1) Postpartum (1) Burn Scar (1)

Modalities

small molecule (3)

Companies

Stony Brook University (1) University of Washington (1) The University of Texas Medical Branch, Galveston (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.